Antibody depletion can treat E. coli-related neurological complications

September 04, 2011

Flushing out the body's IgG antibodies in people with neurological complications after Escherichia coli infection can significantly improve symptoms, according to an Article published by The Lancet. This finding, along with the pattern of neurological complications occurring 1 week after the onset of enteritis, suggests that antibodies against E. coli caused the neurological problems seen in the 2011 outbreak of the bacterium, say the authors.

During the E. coli outbreak in Europe earlier this year, Prof Andreas Greinacher, Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin, Greifswald, Germany, and colleagues suspected the timing of the onset of neurological problems implicated the bodies' own antibodies. The researchers treated 12 patients aged 38-63 years who had severe neurological complications associated with haemolytic uraemic syndrome with a technique called IgG immunoadsorption, which removes the circulating immunoglobulins. To prevent other infection, the patients were infused with intravenous IgG after two rounds of immunoadsorption. All 12 patients survived, and ten had complete neurological and renal function recovery. The team scored the patients neurological impairment, such as hallucinations or aphasia, daily, and immunoadsorption improved this score.

Before immunoadsorption, the patients' symptoms had not responded to plasma exchange and eculizumab (a monoclonal antibody that blocks complement, a component of the immune response).

The findings offer important clues to the mechanisms behind the neurological symptoms. The authors say: "The rapid response that we noted to immunoadsorption makes it unlikely that all neurological symptoms and signs reported were caused by a direct toxic effect of the α subunit of Shiga toxin within the neurons."

They conclude that "immunoadsorption is much more effective in removing antibodies than is therapeutic plasma exchange, which is the treatment most often used for severe microangiopathy-associated organ dysfunction, including severe haemolytic uraemic syndrome."

In a linked Comment, Jon Jin Kim, Evelina Children's Hospital, London, who described the study as a "well thought out prospective cohort trial", said: "Immunoadsorption was reported to be a promising therapeutic option for patients with neurological sequelae, and the outcomes suggest a novel pathophysiology involving IgG in diarrhoea-associated haemolytic uraemic syndrome."
-end-
Prof Andreas Greinacher, Ernst-Moritz-Arndt Universität, Institut für Immunologie und Transfusionsmedizin, Klinikum/Sauerbruchstrasse, Greifswald, Germany. T) +49-3838-865482 E) greinach@uni-greifswald.de

Dr Jon Jin Kim, Evelina Children's Hospital, Paediatric Nephrology, London, UK. E) jonjinkim@doctors.org.uk

Lancet

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.